RU2016135788A - Иммуноконъюгаты интерлейкина 10 - Google Patents
Иммуноконъюгаты интерлейкина 10 Download PDFInfo
- Publication number
- RU2016135788A RU2016135788A RU2016135788A RU2016135788A RU2016135788A RU 2016135788 A RU2016135788 A RU 2016135788A RU 2016135788 A RU2016135788 A RU 2016135788A RU 2016135788 A RU2016135788 A RU 2016135788A RU 2016135788 A RU2016135788 A RU 2016135788A
- Authority
- RU
- Russia
- Prior art keywords
- fusion protein
- seq
- paragraphs
- protein according
- mutant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461936642P | 2014-02-06 | 2014-02-06 | |
| US61/936,642 | 2014-02-06 | ||
| PCT/EP2015/052119 WO2015117930A1 (en) | 2014-02-06 | 2015-02-03 | Interleukine 10 immunoconjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016135788A true RU2016135788A (ru) | 2018-03-07 |
| RU2016135788A3 RU2016135788A3 (https=) | 2018-10-12 |
Family
ID=52440687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016135788A RU2016135788A (ru) | 2014-02-06 | 2015-02-03 | Иммуноконъюгаты интерлейкина 10 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150218244A1 (https=) |
| EP (1) | EP3102594A1 (https=) |
| JP (3) | JP2017506075A (https=) |
| KR (1) | KR20160117463A (https=) |
| CN (1) | CN106061997A (https=) |
| AR (1) | AR099288A1 (https=) |
| BR (1) | BR112016016658A2 (https=) |
| CA (1) | CA2935665A1 (https=) |
| MX (1) | MX2016010174A (https=) |
| RU (1) | RU2016135788A (https=) |
| TW (1) | TW201613954A (https=) |
| WO (1) | WO2015117930A1 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20150645A1 (es) | 2012-08-08 | 2015-05-11 | Roche Glycart Ag | Proteinas de fusion de interleuquina 10 y usos de las mismas |
| EP3224275B1 (en) | 2014-11-14 | 2020-03-04 | F.Hoffmann-La Roche Ag | Antigen binding molecules comprising a tnf family ligand trimer |
| AU2015364396B2 (en) | 2014-12-19 | 2018-08-09 | Alkermes, Inc. | Single chain Fc fusion proteins |
| EP3973980A1 (en) | 2015-03-31 | 2022-03-30 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a trimeric tnf family ligand |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| US10526413B2 (en) | 2015-10-02 | 2020-01-07 | Hoffmann-La Roche Inc. | Bispecific antibodies specific for OX40 |
| RU2018124307A (ru) * | 2015-12-04 | 2020-01-14 | Новартис Аг | Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции |
| WO2018005226A2 (en) | 2016-06-22 | 2018-01-04 | Alkermes, Inc. | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
| JP7626577B2 (ja) | 2016-11-28 | 2025-02-07 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
| BR112019008727A2 (pt) | 2016-11-28 | 2019-07-16 | Chugai Seiyaku Kabushiki Kaisha | domínio de ligação ao antígeno, e polipeptídeo incluindo seção de transporte |
| CN108948207B (zh) * | 2017-05-22 | 2020-11-13 | 杭州博虎生物科技有限公司 | 一种人白细胞介素10-Fc融合蛋白及其编码基因与应用 |
| MY206158A (en) | 2017-05-24 | 2024-12-02 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
| EP4029877B1 (en) | 2017-08-03 | 2024-01-17 | Amgen Inc. | Interleukin-21 muteins and methods of treatment |
| JP7710706B2 (ja) | 2017-09-25 | 2025-07-22 | シーフイダ ファーマシューティカル グループ （チーリン） カンパニー リミテッド | 癌治療のための方法及び組成物 |
| US20200353050A1 (en) * | 2017-11-10 | 2020-11-12 | Armo Biosciences, Inc. | Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors |
| JP7482630B2 (ja) | 2017-11-28 | 2024-05-14 | 中外製薬株式会社 | 抗原結合ドメインおよび運搬部分を含むポリペプチド |
| TWI880235B (zh) | 2017-11-28 | 2025-04-11 | 日商中外製藥股份有限公司 | 可調整配體結合活性的配體結合分子 |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
| WO2020037043A1 (en) | 2018-08-15 | 2020-02-20 | The Regents Of The University Of California | Il-10 inhibition for vaccines and immunotherapy |
| CN112654641A (zh) * | 2018-10-01 | 2021-04-13 | 豪夫迈·罗氏有限公司 | 具有与cd40的三价结合的双特异性抗原结合分子 |
| JP2022512746A (ja) * | 2018-10-19 | 2022-02-07 | アンブルックス，インコーポレイテッド | インターロイキン－１０ポリペプチド複合体、その二量体、およびそれらの使用 |
| WO2020097946A1 (zh) * | 2018-11-18 | 2020-05-22 | 杭州博虎生物科技有限公司 | 一种重组人白细胞介素10融合蛋白及其应用 |
| EP3927728A2 (en) | 2019-02-21 | 2021-12-29 | Xencor, Inc. | Untargeted and targeted il-10 fc-fusion proteins |
| CN121652287A (zh) * | 2019-03-06 | 2026-03-13 | 德卡生物科学公司 | Il-10变体分子和治疗炎性疾病和肿瘤的方法 |
| WO2020229378A1 (en) * | 2019-05-13 | 2020-11-19 | F. Hoffmann-La Roche Ag | Interference-suppressed pharmacokinetic immunoassay |
| CN114599390A (zh) * | 2019-06-10 | 2022-06-07 | 浙江冠科美博生物科技有限公司 | 抗体-白介素融合蛋白以及使用方法 |
| JP2022540187A (ja) * | 2019-07-08 | 2022-09-14 | プロジェン・カンパニー・リミテッド | 新規融合タンパク質及びその用途 |
| CN112618698B (zh) * | 2019-10-08 | 2021-10-08 | 北京东方百泰生物科技股份有限公司 | 一种人白细胞介素10-Fc融合蛋白的注射制剂 |
| CN112625137B (zh) * | 2019-10-08 | 2021-10-08 | 北京东方百泰生物科技股份有限公司 | 一种人白细胞介素10-Fc融合蛋白及其医药用途 |
| FI4065585T3 (fi) | 2019-11-25 | 2025-09-26 | Alkermes Inc | Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä |
| EP4087947A4 (en) * | 2020-01-09 | 2024-05-01 | Deka Biosciences, Inc. | METHODS OF USING GENETIC MARKERS, SNPS AND/OR INDELS TO DETERMINE SENSITIVITY TO IL-10 TREATMENT |
| EP4093875A4 (en) * | 2020-01-20 | 2024-02-28 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding fusion proteins |
| WO2021231447A1 (en) | 2020-05-12 | 2021-11-18 | Regeneron Pharmaceuticals, Inc. | Novel il10 agonists and methods of use thereof |
| WO2021230460A1 (ko) * | 2020-05-14 | 2021-11-18 | 주식회사 제넥신 | Pd-l1 단백질 및 단량체성 il-10 변이체가 포함된 융합 단백질 및 이의 용도 |
| CA3180304A1 (en) * | 2020-05-28 | 2021-12-02 | Kenan Christopher GARCIA | Engineered interleukin-10 polypeptides and uses thereof |
| PE20231082A1 (es) * | 2020-06-26 | 2023-07-17 | Amgen Inc | Muteinas de il-10 y proteinas de fusion de las mismas referencia cruzada a solicitudes relacionadas |
| CA3186753A1 (en) | 2020-07-20 | 2022-01-27 | John Mumm | Dual cytokine fusion proteins comprising il-10 |
| CA3204723A1 (en) * | 2020-12-09 | 2022-06-16 | Asher Biotherapeutics, Inc. | Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function |
| KR20230129983A (ko) * | 2020-12-09 | 2023-09-11 | 애셔 바이오테라퓨틱스, 인크. | 조작된 세포 요법을 위한 표적화된 사이토카인 구축물 |
| IL303501A (en) * | 2020-12-10 | 2023-08-01 | Biocad Joint Stock Co | Immunogenic cytokine for activation of the human IL-10RA receptor and its use |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| WO2023078245A1 (zh) * | 2021-11-02 | 2023-05-11 | 广东菲鹏制药股份有限公司 | Il10单体融合蛋白及其应用 |
| US20240190934A1 (en) * | 2022-11-28 | 2024-06-13 | Elixiron Immunotherapeutics (hong Kong) Limited | Engineered interleukin-10 and fusion proteins thereof |
| CN118240058A (zh) * | 2022-12-24 | 2024-06-25 | 广东菲鹏制药股份有限公司 | Il10突变体、融合蛋白和药物 |
| EP4647489A1 (en) * | 2023-01-03 | 2025-11-12 | Shenzhen Synthetica Pioneering Co., Ltd. | Bacteria secreting interleukin-10 |
| EP4719457A2 (en) * | 2023-06-02 | 2026-04-08 | Synthekine, Inc. | Fused il10 polypeptides |
| TW202540200A (zh) * | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| TW202535949A (zh) | 2023-12-20 | 2025-09-16 | 美商必治妥美雅史谷比公司 | 靶向IL-18受體β(IL-18RB)之抗體及相關方法 |
| CN121343001A (zh) * | 2024-07-16 | 2026-01-16 | 广东菲鹏制药股份有限公司 | 一种融合蛋白及其用途 |
| CN119331091B (zh) * | 2024-11-06 | 2025-05-13 | 重庆探生科技有限公司 | 一种抗人白介素6的单克隆抗体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6428985B1 (en) * | 1998-12-02 | 2002-08-06 | The Regents Of The University Of Michigan | Immunosuppressive structural definition of IL-10 |
| EP2471813B1 (en) * | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| CA2648484A1 (en) * | 2006-05-08 | 2007-11-15 | Philogen Spa | Antibody-targeted cytokines for therapy |
| DK3281952T3 (da) * | 2007-10-30 | 2020-08-03 | Philogen Spa | Antigen, der er forbundet med reumatoid artritis |
| WO2010005389A1 (en) * | 2008-07-11 | 2010-01-14 | Forskarpatent I Syd Ab | Oxidized ldl specific antibody-fusion and conjugated proteins |
| NO2344540T3 (https=) * | 2008-10-02 | 2018-04-28 | ||
| CA2806021C (en) * | 2010-08-13 | 2019-05-21 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
| ES2692268T5 (en) * | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| PE20150645A1 (es) * | 2012-08-08 | 2015-05-11 | Roche Glycart Ag | Proteinas de fusion de interleuquina 10 y usos de las mismas |
-
2015
- 2015-02-03 WO PCT/EP2015/052119 patent/WO2015117930A1/en not_active Ceased
- 2015-02-03 KR KR1020167021279A patent/KR20160117463A/ko not_active Withdrawn
- 2015-02-03 CN CN201580006766.3A patent/CN106061997A/zh active Pending
- 2015-02-03 EP EP15701991.0A patent/EP3102594A1/en not_active Withdrawn
- 2015-02-03 RU RU2016135788A patent/RU2016135788A/ru not_active Application Discontinuation
- 2015-02-03 JP JP2016550540A patent/JP2017506075A/ja active Pending
- 2015-02-03 BR BR112016016658-2A patent/BR112016016658A2/pt not_active Application Discontinuation
- 2015-02-03 MX MX2016010174A patent/MX2016010174A/es unknown
- 2015-02-03 CA CA2935665A patent/CA2935665A1/en not_active Abandoned
- 2015-02-04 US US14/613,987 patent/US20150218244A1/en not_active Abandoned
- 2015-02-05 TW TW104103942A patent/TW201613954A/zh unknown
- 2015-02-05 AR ARP150100324A patent/AR099288A1/es unknown
-
2020
- 2020-01-06 JP JP2020000462A patent/JP2020089371A/ja not_active Withdrawn
-
2022
- 2022-03-15 JP JP2022040084A patent/JP2022095643A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015117930A1 (en) | 2015-08-13 |
| EP3102594A1 (en) | 2016-12-14 |
| JP2017506075A (ja) | 2017-03-02 |
| CN106061997A (zh) | 2016-10-26 |
| JP2022095643A (ja) | 2022-06-28 |
| RU2016135788A3 (https=) | 2018-10-12 |
| KR20160117463A (ko) | 2016-10-10 |
| US20150218244A1 (en) | 2015-08-06 |
| MX2016010174A (es) | 2016-11-15 |
| AR099288A1 (es) | 2016-07-13 |
| CA2935665A1 (en) | 2015-08-13 |
| JP2020089371A (ja) | 2020-06-11 |
| BR112016016658A2 (pt) | 2018-01-23 |
| TW201613954A (en) | 2016-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016135788A (ru) | Иммуноконъюгаты интерлейкина 10 | |
| JP2017506075A5 (https=) | ||
| US20230331813A1 (en) | TIM-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND TIM-3 ANTIGEN BINDING DOMAINS | |
| US20230279071A1 (en) | LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS | |
| JP7560507B2 (ja) | ＣＤ４０Ｌ特異的Ｔｎ３由来足場およびその使用方法 | |
| JP2015530983A5 (https=) | ||
| US9708402B2 (en) | Anti-BAFF-anti-IL-17 bispecific antibodies | |
| JP2019527047A (ja) | ソマトスタチン受容体２に結合するヘテロ二量体抗体 | |
| US20220227867A1 (en) | ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS | |
| AU2016226098A1 (en) | Modified-IgG antibodies that bind Transforming Growth Factor-Beta1 with high affinity, avidity and specificity | |
| EP3688030B1 (en) | Specific binding molecules | |
| US20240010695A1 (en) | Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function | |
| EP4527850A2 (en) | Scfv-fc dimers that bind transforming growth factor-beta1 with high affinity, avidity and specificity | |
| RU2019123112A (ru) | Анти-il-5 антитела | |
| WO2024046301A1 (zh) | 包含taci多肽的融合蛋白及其用途 | |
| CN115151567A (zh) | 治疗性Fc组合物的化学诱导结合和解离以及T细胞接合器与人血清白蛋白的化学诱导二聚化 | |
| CN116829577A (zh) | 用于调节免疫细胞功能的突变型白介素-10多肽与抗原结合分子的融合物 | |
| CA2978459C (en) | Scfv-fc dimers that bind transforming growth factor-.beta.1 with high affinity, avidity and specificity | |
| WO2026072963A1 (en) | Bispecific antibodies that bind tnfrsf25 and il-23/il-23r | |
| HK40117203A (en) | Scfv-fc dimers that bind transforming growth factor-beta1 with high affinity, avidity and specificity | |
| WO2023138639A1 (zh) | 靶向tigit的抗原结合蛋白及其用途 | |
| HK1201862B (en) | Anti-baff-anti-il-17 bispecific antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190409 |